Antengene Corporation Limited (HK:6996)
:6996
Top Page
Antengene Corporation Limited
(6996)
Select Model
Select Model
Rating:41Neutral
Price Target:
HK$3.00
▼(-43.07% Downside)
Action:ReiteratedDate:11/19/25
The overall stock score is primarily impacted by financial performance challenges, including significant profitability and cash flow issues. Technical analysis indicates bearish momentum, further weighing on the score. Valuation concerns, highlighted by a negative P/E ratio and lack of dividend yield, also contribute to the low score.
Positive Factors
Revenue Growth
Sustained ~50% revenue growth indicates durable commercial traction and/or milestone/licensing receipts. Over 2–6 months this supports runway, validates clinical progress to partners, and increases probability of securing further milestone or royalty-based income without relying solely on equity raises.
Negative Factors
Severe Net Losses
Extremely negative net margins signal that operating costs far outstrip revenues, creating structural cash burn. Without material margin improvement or sustained milestone inflows, the company will likely need external funding, diluting shareholders and constraining long-term R&D and commercialization plans.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Sustained ~50% revenue growth indicates durable commercial traction and/or milestone/licensing receipts. Over 2–6 months this supports runway, validates clinical progress to partners, and increases probability of securing further milestone or royalty-based income without relying solely on equity raises.
Read all positive factors
Antengene Corporation Limited (6996) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$3.40B
Dividend YieldN/A
Average Volume (3M)1.88M
Price to Earnings (P/E)―
Beta (1Y)2.16
Revenue Growth49.64%
EPS Growth59.58%
CountryHK
Employees169
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.30
Shares Outstanding679,446,660
10 Day Avg. Volume1,689,397
30 Day Avg. Volume1,876,149
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.45
Price to Sales (P/S)4.12
P/FCF Ratio-0.99
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$10.00Price Target Upside89.75% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)HK$703.70M
Antengene Corporation Limited Business Overview & Revenue Model
Company Description
Antengene Corporation Limited (6996) is a biotechnology company focused on the discovery, development, and commercialization of innovative therapies for cancer treatment. The company operates primarily in the biopharmaceutical sector, concentratin...
How the Company Makes Money
Antengene Corporation generates revenue through multiple streams, primarily from the sale of its proprietary cancer therapies once they are approved and commercialized. The company invests significantly in research and development to bring its dru...
Antengene Corporation Limited Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
60
Neutral
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.35M | 91.95M | 67.31M | 160.13M | 28.77M | 0.00 |
| Gross Profit | 65.15M | 74.17M | 55.01M | 132.00M | 24.19M | 0.00 |
| EBITDA | -268.37M | -348.82M | -550.31M | -866.06M | -614.32M | -501.94M |
| Net Income | -228.59M | -319.25M | -581.18M | -601.49M | -655.53M | -2.93B |
Balance Sheet | ||||||
| Total Assets | 1.27B | 1.34B | 1.62B | 2.14B | 2.56B | 3.19B |
| Cash, Cash Equivalents and Short-Term Investments | 794.19M | 900.24M | 1.19B | 1.79B | 2.37B | 3.11B |
| Total Debt | 234.85M | 249.44M | 201.02M | 57.95M | 14.81M | 10.92M |
| Total Liabilities | 499.29M | 493.93M | 471.20M | 428.84M | 163.29M | 156.59M |
| Stockholders Equity | 766.33M | 850.80M | 1.15B | 1.71B | 2.39B | 3.04B |
Cash Flow | ||||||
| Free Cash Flow | -194.19M | -382.57M | -778.87M | -665.56M | -581.04M | -358.87M |
| Operating Cash Flow | -149.99M | -321.96M | -665.77M | -572.18M | -557.65M | -307.12M |
| Investing Cash Flow | 370.46M | 345.24M | 587.07M | -208.16M | -103.88M | -600.57M |
| Financing Cash Flow | 52.46M | 45.17M | 131.84M | -20.73M | -81.29M | 2.79B |
Antengene Corporation Limited Technical Analysis
Positive
5.27
Price Trends
3.83
Positive
4.06
Positive
4.67
Positive
Market Momentum
0.37
Negative
71.01
Negative
87.11
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Positive. The current price of 5.27 is above the 20-day moving average (MA) of 4.42, above the 50-day MA of 3.83, and above the 200-day MA of 4.67, indicating a bullish trend. The MACD of 0.37 indicates Negative momentum. The RSI at 71.01 is Negative, neither overbought nor oversold. The STOCH value of 87.11 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6996.
Antengene Corporation Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | HK$3.86B | -16.66 | -14.53% | ― | 9.41% | -32.69% | |
54 Neutral | HK$18.61B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | HK$2.37B | -14.44 | -27.70% | ― | -100.00% | 30.68% | |
44 Neutral | HK$2.16B | -3.21 | -137.11% | ― | ― | -18.99% | |
43 Neutral | HK$1.83B | -6.43 | 293.08% | ― | ― | 27.90% | |
41 Neutral | HK$3.40B | -9.15 | -26.73% | ― | 49.64% | 59.58% |
* Healthcare Sector Average
HK:6996
Antengene Corporation Limited
5.36
3.01
128.09%
HK:1672
Ascletis Pharma, Inc.
17.54
12.62
256.50%
HK:1875
TOT BIOPHARM International Co. Ltd.
4.99
3.41
215.82%
HK:2179
Jiangsu Recbio Technology Co., Ltd. Class H
4.50
-2.46
-35.34%
HK:3681
SinoMab Bioscience Ltd.
1.72
0.53
44.54%
HK:6978
Immunotech Biopharm Ltd
2.96
-0.31
-9.48%
Antengene Corporation Limited Corporate Events
Antengene’s XPOVIO® Gains New Approval in Malaysia for Lymphoma Treatment
Dec 16, 2025
Antengene Corporation Limited announced that the Malaysian National Pharmaceutical Regulatory Agency has approved a supplemental New Drug Application for XPOVIO® (selinexor) to treat adult patients with relapsed or refractory diffuse large B-...
Antengene Corporation Enhances Governance with New Committee
Dec 12, 2025
Antengene Corporation Limited has established a Nomination and Corporate Governance Committee as part of its corporate governance framework. This committee, formed by a board resolution on August 18, 2020, is tasked with overseeing the nomination ...
Antengene’s XPOVIO® Gains New Approvals in Hong Kong
Dec 3, 2025
Antengene Corporation Limited announced that the Hong Kong Department of Health has approved two supplemental New Drug Applications for XPOVIO® (selinexor) for additional indications in multiple myeloma and diffuse large B-cell lymphoma. This...
Antengene Secures IND Approval for ATG-022 Study in China
Dec 2, 2025
Antengene Corporation Limited announced that the China National Medical Products Administration has approved the investigational new drug application for a Phase Ib/II study of ATG-022 in combination with KEYTRUDA and chemotherapy. This approval m...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.